Clinical Trials Browser

Adenocarcinoma

NCT06834204 2026-03-23

ACCESS-PC

Adenocarcinoma, Urinary Bladder Neoplasms, Diabetes Mellitus, Hypercholesterolemia, Hyperlipidemias, Hypertension, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07455422 2026-03-06

Endeavor-2

Phase NA Not yet recruiting

266 enrolled

Gastrointestinal

Adenocarcinoma, Barrett Esophagus

NCT07444983 2026-03-03

Rezvilutamide for High-Risk Prostate Cancer After Surgery

Phase NA Not yet recruiting

33 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06794073 2025-08-29

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Phase NA Not yet recruiting

17 enrolled

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Glandular and Epithelial

NCT06931496 2025-04-17

PROSTIA- BP

Phase NA Not yet recruiting

150 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06915909 2025-04-08

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial

Phase NA Not yet recruiting

40 enrolled

Genitourinary

Adenocarcinoma, Pain, Pain, Postoperative, Prostatic Neoplasms

NCT06844513 2025-02-25

URO-ROBOT-2023

Phase NA Not yet recruiting

800 enrolled

Genitourinary

Adenocarcinoma, Kidney Neoplasms, Prostatic Neoplasms

Clinical Trials

AAPICO

ACCESS-PC

Endeavor-2

Rezvilutamide for High-Risk Prostate Cancer After Surgery

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

PROSTIA- BP

Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial

URO-ROBOT-2023